Contact-
SARS-CoV-2
ChLIA from EUROIMMUN
Anti-SARS-CoV-2 RBD ChLIA (IgG)
- Chemiluminescence immunoassay for quantitative measurement of IgG against the receptor-binding domain (RBD) of SARS-CoV-2
- Suited for the determination of the IgG antibody response following wild-type infections as well as vaccination with spike protein-based vaccines
- Conversion into standardised units (BAU/ml) possible
- Excellent agreement with the already established S1-based SARS-CoV-2 IgG ELISAs from EUROIMMUN
- Exclusively processed automatically using the random access instruments IDS-i10 and IDS-iSYS Multi-Discipline Automated System (from software version 15.06a): continuous loading of patient samples for maximum flexibility
| Product | Ig class | Format | Included controls | Order no. | Status |
|---|---|---|---|---|---|
| Anti-SARS-CoV-2 RBD ChLIA (IgG) | IgG | 100 analyses, 4 x 5 ml | Additional product | LI 2606-10010-1 G | CE marked |
| Control set Anti-SARS-CoV-2 RBD ChLIA (IgG) | IgG | Pos. control, neg. control | LR 2606-20210-1 G | CE marked |